Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 123 results

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

S

Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y et al.. 2021. SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.. Cell Stem Cell.

Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T. 2013. S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.

R

Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, Scherl E, Schnoll-Sussman F, Katz P, Steinlauf A. 2019. Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.. Dig Dis Sci. 64(8):2273-2279.

Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B. 2013. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.

Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW. 2018. Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.

Scherl EJ, Kumar S, Warren RU. 2010. Review of the safety and efficacy of ustekinumab.. Therap Adv Gastroenterol. 3(5):321-8.

J Blander M, Longman RS, Iliev ID, Sonnenberg GF, Artis D. 2017. Regulation of inflammation by microbiota interactions with the host.. Nat Immunol. 18(8):851-860.

Longman RS, Moreira RK, Littman DR, Green PHR, Sethi A. 2012. A rare intestinal infection with systemic effects.. Gastroenterol Hepatol (N Y). 8(1):60-3.

Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. 2008. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.

Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al.. 2021. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.

P

Poppers DM, Scherl EJ. 2008. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.. Inflamm Bowel Dis. 14(1):106-13.

Battat R, Long MD. 2021. Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data. Am J Gastroenterol. 116(10):2029-2031.

Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. 2004. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.. Blood. 103(3):1026-9.

Lukin DJ. 2020. Predictors of Perianal Fistula Relapse in Crohn's Disease.. Inflamm Bowel Dis. 26(6):932-933.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al.. 2018. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.

Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML. 2007. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients.. J Exp Med. 204(10):2423-37.

Ghosh G, Jacob V, Wan D. 2018. Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.

Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al.. 2012. Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.

O

Stathopoulos C, Li T, Longman R, Vothknecht UC, Becker HD, Ibba M, Söll D. 2000. One polypeptide with two aminoacyl-tRNA synthetase activities.. Science. 287(5452):479-82.

Kivolowitz C, Abdulhamid A, Victorio D, Castellanos J, Simpson K, Scherl E, Longman R. 2016. O-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.. Inflamm Bowel Dis. 22 Suppl 1:S3.

N

Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. 2005. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.. J Infect Dis. 192(3):497-503.

Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS. 2021. No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.. Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.

M

Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al.. 2013. Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.

Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR et al.. 2018. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.. Immunity. 49(6):1077-1089.e5.

Diehl GE, Longman RS, Zhang J-X, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR. 2013. Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.. Nature. 494(7435):116-20.